---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-003778"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2026-05-29T11:40:17+00:00"
generated_at: "2026-05-29T11:45:10.806538+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aptose delays Hanmi acquisition closing to June 2026 on pending Korean regulatory approvals

## Summary
- Closing of plan of arrangement with Hanmi delayed to June 2026 as Korean regulatory approvals remain in progress; parties expect closing to occur.
- Shareholders to receive C$2.41 per share (28% premium over 30-day VWAP on the TSX) upon completion.
- Aptose received additional US$2.0M advance under US$11.9M loan facility from Hanmi, total draws now US$9.9M; final US$2.0M expected shortly.
- Advances support uninterrupted continuation of TUSCANY clinical trial for tuspetinib in frontline AML.

## SEC filing metadata
- accession: 0001171843-26-003778
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2026-05-29T11:40:17+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184326003778/0001171843-26-003778-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184326003778/f8k_052926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-003778
- JSON: https://secwatch.observer/filing/0001171843-26-003778.json
- Plain text: https://secwatch.observer/filing/0001171843-26-003778.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.